Publications

Emerging evidence suggests that immunological responses to SARS-CoV-2 mRNA vaccines in solid organ transplant recipients are attenuated, with reported seroconversion rates of less than 60%. However, there are insufficient data on responses to adenoviral vector SARS-CoV-2 vaccines in transplant populations. Here we describe immunological responses to two-dose vaccination with BNT162b2 (Pfizer–BioNTech) and ChAdOx1 (Oxford University–AstraZeneca) in kidney transplant recipients.